Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
about
Prime-boost approaches to tuberculosis vaccine developmentCell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interactionImmune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPsProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Polyethylene glycol-grafted polyethylenimine used to enhance adenovirus gene delivery.rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vectorAdenoviral vector immunity: its implications and circumvention strategies.Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectorsLate endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity.Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectorsCurrent strategies and future directions for eluding adenoviral vector immunityAdenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challengeModulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchiesComparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and DAdenovirus Specific Pre-Immunity Induced by Natural Route of Infection Does Not Impair Transduction by Adenoviral Vaccine Vectors in Mice.Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectorsProtective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferonThe number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexesVaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeysDifferential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in miceIntracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responsesProgress and obstacles in the development of an AIDS vaccine.Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes.Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunityNew insights on adenovirus as vaccine vectors.Innate immunity to adenovirus.Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.Induction of Specific CD8 T Cells against Intracellular Bacteria by CD8 T-Cell-Oriented Immunization Approaches.TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector.Structure-based identification of a major neutralizing site in an adenovirus hexon.Adenovirus vectors block human immunodeficiency virus-1 replication in human alveolar macrophages by inhibition of the long terminal repeat.
P2860
Q27024526-2D5955CF-38B2-42AC-9F69-FB1F67C6FE14Q28744246-B584BC7B-A575-47AF-A9A4-B4B285258CDDQ28768041-2255801E-CB30-4711-A1C9-5992FEF3A8D1Q30226988-1947F788-DEFD-40FC-BCAB-D2FA826BC4EFQ30352927-FB83C115-6AAB-4C22-9BC2-891FEF76270CQ30378897-509AB2E1-C95E-4525-A76D-7C62B94AFF77Q31118305-95E5AFC0-88AD-404E-A024-C3D8A17FD89AQ33386020-84BCE44D-23D9-4915-B020-BBC75AFFEA04Q33565630-59B5822A-7C2C-41D2-A090-BF6777609F74Q34204440-F2C7EDD4-0F69-45E2-B78E-B1CF7DEF8932Q34262192-E3A3CB95-C15E-4A55-8657-CACB6ABDB04CQ34457800-94451C46-0665-4D79-B523-CC9EC38258FCQ34585554-C1E2F787-FE26-43A6-AAB9-239CA5706BD2Q34938294-75BDE160-498A-4AB5-B91B-EB6780608FDDQ34992681-44A99D1D-7CEE-482F-8347-D4DDD8A469F5Q35076828-C571C8EC-8B95-440B-A4C8-3CFFABEEFE01Q35185997-27CBEDE7-00DE-416E-8CEA-FDA918BDF42BQ35857420-C81546D0-72EB-4260-9AE0-4E14766E8C89Q35871976-F8F4C627-22F7-430A-BE3A-15D0AA7231A5Q35947690-7BEC34F2-6B71-4280-B0E0-0CD4181A35B0Q35949758-A545A436-C2C5-4162-8907-6389C80A4463Q36023055-EE728D19-A3BC-4D45-800C-A725D760A34DQ36246264-D15F67F4-570F-4414-B868-2230CF42C303Q36291682-1705E320-7B37-4D2C-8701-6D93A01A032BQ36539060-922F25D1-9723-425F-B777-5FE4EC6BBF97Q36628042-36D2F5DB-779E-4AC4-9D81-AD15F7843B55Q36662462-A6991302-DE63-436E-A884-6DF4DD7ABE1EQ36759754-EB8FB8F9-CE71-4B6E-8A43-FABA0CE1EF37Q37067254-96048FEF-2CA7-4FAC-B51A-FA7AD413809AQ37245921-7F3619D0-D69A-4B7E-A0E0-5D6A6AB92333Q37247948-2E923EA8-E317-4045-BF85-6722551F0118Q37513550-DB6943D9-2A5F-4630-8F38-3588F2AE6C01Q37718852-FC59E54C-B13F-4D51-8464-2FA07E74A009Q38284700-C0F441FE-C44B-4588-B856-B846EC34DC67Q39581144-1726C925-04A2-46A0-9148-788F489FF9A2Q40333540-61AE491C-7355-4287-BE0E-FD37497137FEQ40730694-0C8AB53B-5C10-4B52-B6BD-1C1D64349D11Q42131157-5FEEA1DB-FE3B-4FC7-B277-75DDC2BB5C02Q42259707-C974435C-F985-4C41-8160-ACF464DA854BQ42428565-817BD0E2-65BC-4E99-A5BD-7D49D6DE3384
P2860
Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immunogenicity of recombinant ...... es in mice and rhesus monkeys.
@en
Immunogenicity of recombinant ...... es in mice and rhesus monkeys.
@nl
type
label
Immunogenicity of recombinant ...... es in mice and rhesus monkeys.
@en
Immunogenicity of recombinant ...... es in mice and rhesus monkeys.
@nl
prefLabel
Immunogenicity of recombinant ...... es in mice and rhesus monkeys.
@en
Immunogenicity of recombinant ...... es in mice and rhesus monkeys.
@nl
P2093
P2860
P1433
P1476
Immunogenicity of recombinant ...... es in mice and rhesus monkeys.
@en
P2093
Angela Carville
Angelique A C Lemckert
Anjali Nanda
Bonnie A Ewald
Dan H Barouch
Darci A Gorgone
Diana M Lynch
Diana M Truitt
Keith G Mansfield
P2860
P304
14161-14168
P356
10.1128/JVI.79.22.14161-14168.2005
P407
P577
2005-11-01T00:00:00Z